Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
mTOR pathway activation drives lung cell senescence and emphysema
Amal Houssaini, … , Silke Meiners, Serge Adnot
Amal Houssaini, … , Silke Meiners, Serge Adnot
Published February 8, 2018
Citation Information: JCI Insight. 2018;3(3):e93203. https://doi.org/10.1172/jci.insight.93203.
View: Text | PDF
Research Article Aging Pulmonology

mTOR pathway activation drives lung cell senescence and emphysema

  • Text
  • PDF
Abstract

Chronic obstructive pulmonary disease (COPD) is a highly prevalent and devastating condition for which no curative treatment is available. Exaggerated lung cell senescence may be a major pathogenic factor. Here, we investigated the potential role for mTOR signaling in lung cell senescence and alterations in COPD using lung tissue and derived cultured cells from patients with COPD and from age- and sex-matched control smokers. Cell senescence in COPD was linked to mTOR activation, and mTOR inhibition by low-dose rapamycin prevented cell senescence and inhibited the proinflammatory senescence-associated secretory phenotype. To explore whether mTOR activation was a causal pathogenic factor, we developed transgenic mice exhibiting mTOR overactivity in lung vascular cells or alveolar epithelial cells. In this model, mTOR activation was sufficient to induce lung cell senescence and to mimic COPD lung alterations, with the rapid development of lung emphysema, pulmonary hypertension, and inflammation. These findings support a causal relationship between mTOR activation, lung cell senescence, and lung alterations in COPD, thereby identifying the mTOR pathway as a potentially new therapeutic target in COPD.

Authors

Amal Houssaini, Marielle Breau, Kanny Kebe, Shariq Abid, Elisabeth Marcos, Larissa Lipskaia, Dominique Rideau, Aurelien Parpaleix, Jin Huang, Valerie Amsellem, Nora Vienney, Pierre Validire, Bernard Maitre, Aya Attwe, Christina Lukas, David Vindrieux, Jorge Boczkowski, Genevieve Derumeaux, Mario Pende, David Bernard, Silke Meiners, Serge Adnot

×

Figure 8

Effects of mTOR overactivation in SPC-TSC1–/– and PDGF-TSC1–/– mice.

Options: View larger image (or click on image) Download as PowerPoint
Effects of mTOR overactivation in SPC-TSC1–/– and PDGF-TSC1–/– mice.
TSC...
TSC1 deletion was induced by i.p. tamoxifen in PDGF-TSC1–/– mice and by treatment with doxycycline in drinking water in SPC-TSC1–/– mice. The mice were investigated 3 and 6 months later and were compared with vehicle-treated mice. (A) Development of lung emphysema in PDGF-TSC1–/– and SPC-TSC1–/– mice. From left to right, representative lung sections stained with H&E and showing emphysema lesions in PDGF-TSC1–/– and SPC-TSC1–/– mice, mean linear intercept of alveolar septa, and air space. Scale bars: 200 μm. (B) Development of pulmonary hypertension in PDGF-TSC1–/– and SPC-TSC1–/– mice. Right ventricular systolic pressure (RVSP), right ventricular/left ventricular + septum weight ratio (RV/LV+S), and muscularization of pulmonary vessels (percent of muscularized vessels over the total number of pulmonary vessels). Representative pulmonary vessels in PDGF-TSC1–/– and SPC-TSC1–/– mice compared with control mice. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control mice (1-way ANOVA). Scale bars: 50 μm.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts